The earnings call showcased strong revenue growth for OJEMDA, a robust financial position, and progress in clinical trials and regulatory processes, despite some seasonal challenges and high operating expenses.

Company Guidance -

Q2 2025

During the first quarter of the fiscal year 2025, Day One reported strong financial performance and continued growth in the use of its product, OJEMDA, which is being positioned as the standard of care in second-line plus pediatric low-grade glioma (pLGG). OJEMDA's quarterly prescriptions increased by 16% from the previous quarter, driving net product revenue to $30.5 million. The company observed a consistent growth trajectory, with over 2,500 total prescriptions since launch. The commercial strategy focuses on expanding physician adoption and increasing the depth of prescribing among current users. Day One maintains a solid financial foundation, with operating expenses at $68.9 million and a cash balance of $473 million, allowing them to invest strategically without the need for additional financing. The company also advances its clinical pipeline, including the FIREFLY-2 trial and the DAY301 program, aiming to expand its portfolio and sustain long-term growth.

OJEMDA Revenue Growth

OJEMDA achieved $30.5 million in net product revenue in Q1 2025, driven by a 16% increase in prescriptions over the prior quarter and an 11% growth in US net product revenue quarter-over-quarter.

Strong Financial Position

The company reported a cash balance of $473 million with no debt, indicating a solid financial foundation for future growth.

FIREFLY-2 Trial Progress

Enrollment for the global FIREFLY-2 confirmatory trial is progressing well, with expectations to be fully enrolled in the first half of 2026.

EMA Review for Tovorafenib

The EMA accepted Ipsen's application for tovorafenib, advancing its potential availability in the European market.

Day One Biopharmaceuticals (DAWN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DAWN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 05, 2025	2025 (Q2)	-0.36 / -	-0.05	―	―	―
May 06, 2025	2025 (Q1)	-0.44 / -0.35	-0.72	51.39% (+0.37)
Feb 25, 2025	2024 (Q4)	-0.36 / -0.63	-0.63	0.00% (0.00)
Oct 30, 2024	2024 (Q3)	-0.32 / 0.38	-0.54	170.37% (+0.92)
Jul 30, 2024	2024 (Q2)	-0.75 / -0.05	-0.61	91.80% (+0.56)		―
May 06, 2024	2024 (Q1)	-0.66 / -0.72	-0.59	-22.03% (-0.13)	―	―
Feb 26, 2024	2023 (Q4)	-0.57 / -0.63	-0.56	-12.50% (-0.07)	―	―
Nov 06, 2023	2023 (Q3)	-0.59 / -0.54	-0.53	-1.89% (-0.01)	―	―
Aug 07, 2023	2023 (Q2)	-0.61 / -0.61	-0.6	-1.67% (-0.01)	―	―
May 01, 2023	2023 (Q1)	-0.59 / -0.59	-0.48	-22.92% (-0.11)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DAWN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2025	$6.99	$6.30	-9.87%
Feb 25, 2025	$11.82	$9.87	-16.50%
Oct 30, 2024	$14.47	$14.72	+1.73%
Jul 30, 2024	$15.36	$15.19	-1.11%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Day One Biopharmaceuticals (DAWN) report earnings?

Day One Biopharmaceuticals (DAWN) is schdueled to report earning on Aug 05, 2025, After Close (Confirmed).

What is Day One Biopharmaceuticals (DAWN) earnings time?

Day One Biopharmaceuticals (DAWN) earnings time is at Aug 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DAWN EPS forecast?

DAWN EPS forecast for the fiscal quarter 2025 (Q2) is -0.36.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing